期刊文献+

重组杀菌渗透性增加蛋白21在大鼠内毒素血症中保护机制的探讨

Investigation of Protective Mechanism of Recombinant Bactericidal Permeability-increasing Protein 21 in Rat Endotoxemia
下载PDF
导出
摘要 目的探讨重组杀菌渗透性增加蛋白21(rBPI21)在大鼠内毒素血症中保护效应的机制。方法给内毒素血症大鼠注射不同剂量的rBPI21,动态观察rBPI21不同剂量组大鼠血液中内毒素(LPS)、肿瘤坏死因子α(TNF-α)含量的变化。结果rBPI21治疗1组(rBPI21剂量为0.625mg/kg)大鼠,6,12h血浆LPS含量明显低于内毒素组大鼠相同时间点LPS含量(P<0.01),血清TNF-α含量各检测时间点均明显低于内毒素组大鼠相同时间点的含量(P<0.01)。与内毒素组大鼠相比,rBPI21治疗2、3、4组(rBPI21剂量分别为1.25,2.5,5.0mg/kg)大鼠各检测时间点血浆LPS、血清TNF-α含量均明显降低(P<0.01)。结论rBPI21对内毒素血症大鼠的保护作用机制主要是通过促进体内LPS的聚合和清除,降低LPS活性,减少TNF-α等细胞因子的过度表达。 Objective To investigate the protective mechanism of recombinant bactericidal permeability-increasing protein 21 (rBPI 21 ) in rat endotoxemia. Methods Different doses of rBPI 21 were injected in endotoxemia rats and the changes of lipopolysaccharide (LPS) and tumor necrosis factor-α(TNF-α) in blood of all groups were continuously observed. Results 6 and 12 hours after the injection,the levels of LPS in group 1 with rBPI 21 treatment (0.625 mg/kg) were significantly lower than those in endotoxin group at the same time. Serum TNF- α in group 1 with rBPI 21 treatment were lower than those in endotoxin group at any time point (P 〈 0.01 ). Compared with the endotoxin group,the levels of LPS and TNF-α in groups 2,3 and 4 with rBPI 21 treatment (1.25 mg/kg,2.5 mg/kg,5.0 mg/kg,respectively) markedly dropped at any time points(P 〈 0.01 ). Conclusion The protection of rBPI 21 in endotoxemia rots is primarily achieved through neutralizing LPS , decreasing LPS reaction in vivo and inhibiting TNF-α synthesis.
作者 吴丽娜 刘勇
出处 《中国医科大学学报》 CAS CSCD 北大核心 2008年第1期47-49,共3页 Journal of China Medical University
关键词 内毒素 重组杀菌渗透性增加蛋白21 肿瘤坏死因子Α lipopolysaccharide recombinant bactericidal permeability- increasing protein 21 tumor necrosis factor-α
  • 相关文献

参考文献6

  • 1DOBROVOLSKAIA MA,VOGEL SN. Toll receptors,CD14,and macrophage activation and deactivation by LPS [J]. Microbes Infect, 2002,4 (9) : 903 -914.
  • 2LEVY O. Therapeutic potential of the bactericidal/ permeability increasing protein [ J ]. Exp Opin Invest Drug, 2002,11 (2) : 159- 167.
  • 3CURRIE CG,MCCALLUM K,POXTON IR. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease[J]. Med Microbiol,2001,50(4) :345- 354.
  • 4CHABY R. Strategies for the control of LPS-mediated pathophysio-logical disorders [ J ]. Dru g Discov Today, 1999,4 ( 5 ) : 209-221.
  • 5BRIGHTBILL HD, MODLIN RL. Toll-like receptors:molecular mechanisms of the mammalian immune response[J]. Immunology,2000,101 (1):1-10.
  • 6YAO YM,REDL H,BAHRAMI S,et al. The inflammatory basis of trauma/shock associated multiple organ failure [J]. Inflamm Res, 1998,47(5 ) :201-210.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部